Stock Financial Ratios, Dividends, Split History
VRA / Vera Bradley, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||380.77|
|Enterprise Value ($M)||299.94|
|Book Value ($M)||284.69|
|Book Value / Share||7.99|
|Price / Book||1.33|
|NCAV / Share||5.07|
|Price / NCAV||2.78|
|Common Stock Shares Outstanding||35,459,000|
|Weighted Average Number Of Shares Outstanding Basic||35,925,000|
|Common Shares Outstanding||35,519,809|
|Preferred Stock Shares Outstanding||0|
|Weighted Average Number Of Diluted Shares Outstanding||36,026,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.02|
|Return on Assets (ROA)||0.02|
|Return on Equity (ROE)||0.02|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1495320|
|SIC 31 - Leather And Leather Products|
Stock splits are used by Vera Bradley, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Investors interested in stocks from the Retail - Apparel and Shoes sector have probably already heard of Shoe Carnival (SCVL - Free Report) and Vera Bradley (VRA - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
While expansion in the e-commerce space is the success mantra of most retailers, companies like Walmart Inc. (WMT - Free Report) do not ignore the significance of the brick-and-mortar concept. This is evident from the company’s latest store-oriented moves. There were reports that the big-box retailer introduced a convenience store in Plano, TX and has plans rolled up its sleeves to renovate the North Tampa, FL store. (8-0)
The fact that Walmart Inc. (WMT - Free Report) has been trying all means to up the retail game reflects on its latest move to launch convenient and innovative ways to shop this back-to-school season. Most retailers look forward to reap benefits from the extensive consumer spending during this season every year. Amazon (AMZN - Free Report) too is well set to attract customers this season with its extravagant Prime Day offerings on July 16. (9-0)
With rising comparable store sales (comps) aided by steadily growing e-commerce operations and effective merchandising efforts, Kirkland's, Inc. (KIRK - Free Report) has been performing impressively. Such factors have enabled the company to deliver year over year top-line growth for 10 straight quarters now. On the flip side, the company continues to face declining gross margins as well as higher store occupancy and freight costs. (6-0)
Fossil Group, Inc. (FOSL - Free Report) has been nothing less than a gold mine for investors since the beginning of 2018. Well, shares of this renowned watchmaker more than tripled in the past six months compared with the industry’s rise of 5.7%. So, what’s boosting investors’ optimism for this Zacks Rank #2 (Buy) stock? Let’s take a look. Wearables Offer Growth Impetus Fossil owes much of its success to the stupendous growth in connected wearables category. (17-0)
as of ET